Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
MetaVia presented positive preclinical data at ObesityWeek® 2026 comparing its dual-receptor agonist DA-1726 against retatrutide in diet-induced obese mice. The study showed DA-1726 achieved comparable weight loss with less appetite suppression and superior glucose lowering, while significantly increasing hepatic FGF21 expression. The company plans to advance DA-1726 into a Phase 2 study for MetALD and ALD in the second half of 2027.
Nano Dimension Divestiture to QTREX Quantum Ltd. for $16M
Nano Dimension completed the divestiture of its subsidiary Global Inkjet Systems Limited (GIS) to QTREX Quantum Ltd. for $16 million in equity consideration. The deal includes QTREX ordinary shares, pre-funded warrants, and additional warrants, allowing Nano Dimension to retain exposure to GIS's future growth within the quantum computing infrastructure market.
iPower Inc. completed a fourth additional optional closing under its existing senior secured convertible note facility, issuing $2.0 million in principal amount of Series A Notes to an institutional investor. The company received gross proceeds of $1.88 million at a fixed conversion price of $1.488 per share, representing 120% of the recent Nasdaq closing price. To date, the company has sold $17.2 million in Series A Notes under the $30.0 million facility.
WEN Acquisition Signs $1B M&A Deal with Our Next Energy Inc.
Wen Acquisition Corp (WENN), a SPAC, has entered into a definitive business combination agreement with Our Next Energy Inc. (ONE), a U.S.-based LFP battery manufacturer. The transaction values the combined company at a pro forma equity value of approximately $1 billion and is expected to provide up to $400 million in gross proceeds, including a $100 million PIPE. Upon closing in the first half of 2027, the combined company will be named Our Next Energy Holdings, Inc. and is expected to trade on Nasdaq under the ticker ONEE.
Value
$1B
Counterparty
Our Next Energy Inc.
“Over the last five years, LFP has grown from roughly 20% to 60% of the global battery market, yet China produces approximately 99% of the world’s LFP cells. We built ONE to close that gap with a secure American and allied supply chain. We believe our combination with Wen will give us a public platform to scale ONE into this $40B addressable market with access to growth capital as we scale our operations to meet rising demand.”
Mujeeb Ijaz, Founder and CEO of ONE
“ONE has done the hard part of building an American LFP cell and pack business, with factories operating and customers in markets that increasingly require domestic supply. With two operating factories, binding customer contracts, and federal policy appearing to move its way, ONE is positioned to lead the reshoring of critical battery manufacturing in the United States.”
John Marshall Bancorp M&A Deal with Eagle Financial Services, Inc.
John Marshall Bancorp and Eagle Financial Services announced that the Federal Reserve Bank of Richmond has approved the merger of their respective bank subsidiaries, Bank of Clarke and John Marshall Bank. The transaction, originally announced in September 2026, will create a combined community bank with approximately $4.3 billion in total assets. The deal remains subject to approval from the Virginia Bureau of Financial Institutions and shareholders of both companies.
Eagle Financial Services M&A Deal with John Marshall Bancorp, Inc.
Eagle Financial Services, Inc. (EFSI) and John Marshall Bancorp, Inc. (JMSB) announced that the Federal Reserve Bank of Richmond has approved the merger of Bank of Clarke into John Marshall Bank. The transaction, originally announced in September 2026, will create a combined community bank with approximately $4.3 billion in total assets. The deal remains subject to approval from the Virginia Bureau of Financial Institutions and shareholders of both companies at meetings scheduled for November 19, 2026.
Rein Therapeutics announced preliminary blinded Phase 2 data from its RENEW trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). The data showed that 33% of evaluable patients demonstrated improvement in forced vital capacity (FVC) at Week 12, with favorable safety and tolerability observed across the study population.
“As we continue to enroll patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need.”
Brian Windsor, Ph.D., President and Chief Executive Officer
Super League Enterprise, Inc. entered into a securities purchase agreement with accredited investors for a registered direct offering of 150,000 shares of common stock. The offering is priced at $4.00 per share and is expected to result in gross proceeds of approximately $600,000. The transaction is conducted under the company's existing shelf registration statement and is scheduled to close around November 16, 2026.
Arcturus Therapeutics Holdings Capital Raise of $50M
Arcturus Therapeutics entered into a securities purchase agreement with Meiji Seika Pharma for the sale of 2,466,395 shares of common stock at $20.27 per share, raising $50 million in gross proceeds. The investment was made at an 80% premium to the 30-day average closing price and is part of an expanded collaboration including a license agreement for ARCT-154 technology and a pandemic preparedness MOU in Japan.
Value
$50M
Counterparty
Meiji Seika Pharma Co., Ltd.
“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”
Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics
CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint, showing a 68% reduction in the risk of recurrence (hazard ratio of 0.32) compared to the control arm, with no Grade 3 or higher treatment-related adverse events reported.
Surrozen, Inc. entered into an underwriting agreement for a public offering of 1,894,540 shares of common stock at a price of $31.67 per share. The company expects to receive gross proceeds of approximately $60 million from the offering, which is scheduled to close on November 16, 2026.
Value
$60M
Counterparty
Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
Corbus Pharmaceuticals Holdings Clinical Trial Data
Corbus Pharmaceuticals announced positive Phase 1b clinical trial data for CRB-913, an oral non-incretin therapy for obesity, presented at ObesityWeek 2026. The CANYON-1 trial demonstrated statistically significant weight loss across all doses, with the 60 mg cohort achieving a 5% mean weight loss at 12 weeks and a favorable safety profile with low discontinuation rates.
Term
16 weeks
“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
Corvex Wins $103M Contract from scaled AI inference platform
Corvex, Inc. signed a definitive three-year, $103 million take-or-pay agreement to provide NVIDIA Blackwell computing capacity to a scaled AI inference platform. The deployment, which includes over 1,000 NVIDIA HGX B200 GPUs, is expected to cost $78 million and will be funded primarily through a $26 million customer prepayment and $38 million in non-recourse debt financing.
The Children’s Place, Inc. and certain subsidiaries filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of New Jersey. The company secured $282 million in debtor-in-possession (DIP) financing, consisting of a $166 million asset-based revolving facility and a $116 million term loan facility to fund operations and case administration. The financing includes the refinancing of prepetition debt and is subject to court-approved budget and variance compliance.
Strategy Inc reported that it sold 2,087,040 shares of Class A Common Stock (MSTR) under its at-the-market offering program between November 9 and November 15, 2026, generating net proceeds of $244.7 million. The company utilized $33.4 million of these proceeds to purchase 485 additional bitcoins and $206.3 million to fund repurchases of its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC).
Pasithea Therapeutics announced positive initial Phase 1/1b clinical data for PAS-004 in patients with neurofibromatosis type 1 (NF1), showing that all 15 evaluable participants experienced reductions in cutaneous neurofibroma (cNF) surface area. The company also reported that the FDA has cleared its Investigational New Drug (IND) application to proceed with a Phase 2 trial of PAS-004 in adults with NF1-associated cNF.
IX Acquisition Corp. provided a status update regarding its pending business combination involving Parent and Merger Sub. The filing includes forward-looking statements concerning the anticipated initial enterprise value, post-closing equity value, and the expected timing for the consummation of the transaction.
Ameris Bancorp M&A Deal with Bank of Central Florida Holding Company
Ameris Bancorp (ABCB) has entered into a definitive agreement to acquire Bank of Central Florida Holding Company (BOCF) in an all-stock merger transaction. BOCF shareholders will receive 0.6279 shares of Ameris common stock for each share held, representing an implied value of $51.80 per share. The deal expands Ameris's presence in the Lakeland and Tampa markets and is expected to close in the first quarter of 2027.
Surgery Partners M&A Deal with Bon Secours Mercy Health, Inc.
Surgery Partners announced a consent solicitation for its $1.225 billion 7.250% Senior Notes due 2032 to amend the indenture in connection with its pending merger with Spyglass Topco, LLC and Bon Secours Mercy Health. The amendments seek to designate the acquirers as 'Permitted Holders' to prevent the merger from triggering a 'Change of Control' repurchase obligation under the debt agreement.
Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.
Mara Holdings Signs $1.5B M&A Deal with Long Ridge Energy & Power LLC
MARA Holdings subsidiary MARA USA Corporation has commenced a $185 million private offering of senior secured notes to fund its previously announced $1.5 billion acquisition of Long Ridge Energy & Power LLC. The acquisition includes 100% of the membership interests in the target, which is the parent of Long Ridge Energy LLC. Proceeds will also be used to repay existing indebtedness and cover transaction fees.
Medicus Pharma Ltd. entered into a securities purchase agreement for a registered direct offering of 97,973 common shares and 1,646,213 pre-funded warrants for gross proceeds of approximately $3.0 million. Additionally, the company executed a debt-for-equity exchange with Streeterville Capital, LLC, partitioning $10.5 million in principal from an existing secured promissory note into 105,000 non-convertible preferred shares to reduce its debt obligations.
The Macerich Company announced the acquisition of Oakridge Mall, a 1.1 million square foot super-regional retail center in San Jose, California, for approximately $250 million. The acquisition is funded through the partial settlement of 11 million shares of common stock previously sold on a forward basis in June 2026 at an initial forward price of $23.12 per share.
InspireMD, Inc. priced an underwritten public offering of common stock and pre-funded warrants for gross proceeds of approximately $37.5 million. The offering includes 7,342,308 shares of common stock and pre-funded warrants for 50,350,000 shares, each accompanied by Series L warrants. Proceeds are intended for research and development, sales and marketing, and general corporate purposes.
Lexeo Therapeutics announced positive interim Phase I/II data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, showing an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) in high-dose cohorts. The company also reported that the FDA is open to using NSVT as a primary surrogate endpoint to support potential accelerated approval in a planned pivotal study.
“The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM.”
R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics
InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.
InMed Pharmaceuticals Inc. (now renamed Mentari Therapeutics, Inc.) completed its previously announced business combination with private Delaware corporation Mentari Therapeutics on November 6, 2026. This filing provides the required historical financial statements and management's discussion for the acquired Mentari entity for the period ended September 30, 2026. The combined company now trades on Nasdaq under the ticker 'MTRI'.
T1 Energy Inc. entered into an equity distribution agreement to establish an at-the-market (ATM) offering program for the sale of up to $100 million of its common stock. The company intends to use the proceeds to fund the construction of Phase 1 of its G2_Austin infrastructure and for general corporate purposes. Roth Capital Partners will serve as the sales agent and receive a commission of up to 3.00% of gross sales proceeds.
NorthWestern Energy Group M&A Deal with Black Hills Corporation
NorthWestern Energy Group, Inc. completed its merger with Black Hills Corporation, becoming a wholly owned subsidiary of Black Hills. NorthWestern shareholders received 0.98 shares of Black Hills common stock for each share of NorthWestern common stock held. Following the closing, NorthWestern common stock will be delisted from the Nasdaq Stock Market.
Black Hills M&A Deal with NorthWestern Energy Group, Inc.
Bright Horizon Energy Corporation (formerly Black Hills Corp.) completed its all-stock merger with NorthWestern Energy Group, Inc. on November 13, 2026. NorthWestern shareholders received 0.98 shares of the combined company for each share held, and the new entity began trading on the NYSE under the ticker symbol 'HZN'.
Blackstone Digital Infrastructure Trust Signs $5B M&A Deal with Amazon Data Services, Inc.
Blackstone Digital Infrastructure Trust (BXDC) entered into a definitive agreement to acquire a 75.1% controlling interest in two joint ventures with Amazon Data Services (AWS) for $5.0 billion. The transaction covers 13 newly constructed data centers in Indiana and Mississippi totaling 647 megawatts, which will be 100% leased back to Amazon under long-term triple-net leases. The deal represents BXDC's inaugural investment following its IPO and is expected to close in Q4 2026.
Value
$5B
Counterparty
Amazon Data Services, Inc.
Term
12 years
“We are thrilled to announce BXDC’s inaugural investment and our partnership with Amazon, a leading global technology company with a long-term commitment to innovation. The quality, basis and tenant profile of these assets make this an attractive match for the deployment of our IPO proceeds.”
Nick Pell, Chief Executive Officer and President of BXDC
“Partnering with Blackstone allows us to continue expanding responsibly while keeping communities at the center of how we build.”